Skip to main content
BRVE
NASDAQ Life Sciences

Braveheart's HRS/BHB-1893 Holds 52-Week Benefit; Fixed-Dose Phase 2b TRUEHEART-HCM Planned

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$18.3
Mkt Cap
$1.648B
52W Low
$16.7
52W High
$32
52W Position info
9.6% above low
Off High info
43% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

BRVE is trading near its 52-week low of $16.7 (9.6% above the low).

Summary

Braveheart presented 52-week open-label extension data at AHA showing durable exercise-capacity and symptom gains and deep LVOT gradient reduction with HRS/BHB-1893, with most patients staying on the starting dose. The company also outlined a planned fixed-dose Phase 2b oHCM study, TRUEHEART-HCM.


Key Events · Product Development and Regulatory · BRVE

  • 52-Week OLE Data Show Durable Benefit

    At Week 52 of the open-label extension, mean pVO2 rose 2.7 mL/kg/min and KCCQ-CSS rose 17.3 points from OLE baseline; 79% (33/42) achieved Valsalva LVOT-G below 30 mmHg.

  • Majority Stay on Starting Dose

    57% (24/42) of patients ended the study on the 40 mg BID starting dose and 19% (8/42) on 60 mg BID, supporting a simplified, lower-monitoring regimen.

  • Clean Long-Term Safety Profile

    No on-treatment severe or serious adverse events over 52 weeks; all TEAEs were mild or moderate and none led to discontinuation, with two transient LVEF reductions below 50% (48% and 49%) that resumed at a lower dose.

  • Fixed-Dose Phase 2b TRUEHEART-HCM Planned

    Braveheart said the data inform future clinical plans, including a planned fixed-dose Phase 2b study in oHCM (TRUEHEART-HCM), discussed on a same-day investor webcast.


Analysis · BRVE · Life Sciences

The 52-week open-label extension shows the effect holding up rather than fading: mean pVO2 up 2.7 mL/kg/min and KCCQ-CSS up 17.3 points from OLE baseline, with 79% of patients (33/42) below the 30 mmHg Valsalva gradient threshold at Week 52. Just as important commercially, 57% of patients stayed on the 40 mg BID starting dose, which supports a simpler, lower-monitoring regimen than rival cardiac myosin inhibitors — the basis for the planned fixed-dose Phase 2b TRUEHEART-HCM study. Safety was clean over the year (no severe or serious on-treatment events; two transient LVEF dips that resolved on a lower dose). For a clinical-stage company whose entire valuation rests on this asset, durable efficacy plus a dosing advantage is the core thesis evidence, and the nHCM diastolic data open a second, roughly one-third of the HCM population.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRVE was trading at $18.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $16.70 to $32.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRVE - Latest Insights

BRVE
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.39 info
Change: +$0.770 (+4%) info
Market Cap: $1.832B info
BRVE
Nov 10, 2026, 4:03 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.39 info
Change: +$0.770 (+4%) info
Market Cap: $1.832B info
BRVE
Nov 06, 2026, 3:15 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.39 info
Change: +$2.09 (+11%) info
Market Cap: $1.832B info
BRVE
Sep 08, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.41
Real-time Price: $20.39 info
Change: -$9.02 (-31%) info
Market Cap: $1.832B info
BRVE
Aug 14, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $27.03
Real-time Price: $20.39 info
Change: -$6.64 (-25%) info
Market Cap: $1.832B info